PAT-DX1 Significantly Improves Survival in Aggressive GBM
(WorldNews Health)

ASX & Media Release PAT-DX1 significantly improves survival in an animal model of highly aggressive glioblastoma brain tumours Melbourne, Australia; 22 July 2019: Patrys Limited (ASX: PAB, "Patrys`" or the Company), a therapeutic antibody development company, is pleased to announce new pre-clinical animal data for its lead candidate, PAT-DX1. Results of the study provide additional data in support of the potential for PAT-DX1 to improve patient outcomes in glioblastoma (GBM). Key highlights Yale School of Medicine completed a new animal study, further highlighting that PAT-DX1 may have the potential to improve radiation therapy, a common standard of care treatment for GBM...